Hearing Aids Market Size, Share & Forecast 2026-2032
Hearing aids market at $9.37B in 2026, reaching $13.67B by 2032 at 6.5% — and why 23.16 million units at retail prices means consumers spend about $31B.
$9.4B
$13.7B
6.5%
Global
Executive Summary
Hearing aids is the best-instrumented market in this batch, and that is what makes its central defect provable rather than arguable. An industry trade body publishes unit shipments, four of the five major manufacturers publish revenue, one of them publishes wholesale and retail separately in the same statement, and a large buyer survey publishes measured transaction prices. Put them together and the published market sizes are revealed as a single unstated scope decision. EHIMA's members sold 23.16 million hearing aids globally in 2025; divide the published totals by that count and you get $380 to $652 per aid, which is a factory-gate price. HearingTracker's survey of more than 1,100 buyers puts the measured average at $2,694 per pair, or $1,347 per aid, so consumer spend on those same units is roughly $31.2 billion — about 3.5 times the $8.8 billion headline. Demant proves the two tiers from inside one company: 2025 retail clinic revenue of DKK 10,724 million, up 8%, against external wholesale hearing-aid revenue of DKK 9,841 million, down 2%. Four manufacturers' disclosed revenue totals about $11,769 million, exceeding three of the five published figures, with Starkey absent and Amplifon outside every definition — and the excess reconciles exactly once retail is stripped out, landing the manufacturer tier back at roughly $8 to $9 billion. We publish that tier: $9.37 billion in 2026 to $13.67 billion by 2032 at 6.5%. The warning attached is that unit growth has fallen from 7.7% to 2.1% in two years, measured consumer prices are down 42% since 2018 following the FDA's October 2022 over-the-counter rule, and the manufacturers' own 2025 growth was 2 to 3%.
Key Highlights
Headline
$9.37 billion in 2026 to $13.67 billion in 2032 at 6.5%, interpolated from Global Market Insights' own published 2025 base and rate — the manufacturer tier
EHIMA members sold 23.16 million hearing aids globally in 2025, so the published totals work out at $380 to $652 per aid: a factory-gate price, not a retail one
At HearingTracker's measured $1,347 per aid, consumer spend on those 23.16 million units is roughly $31.2 billion — about 3.5x the published figure
Demant's 2025 retail revenue (DKK 10,724 million, +8%) exceeded its own external wholesale hearing-aid revenue (DKK 9,841 million, -2%), proving the two tiers from inside one company
Four manufacturers disclose about $11,769 million between them — 1.34x Global Market Insights' $8.8 billion — with Starkey absent and Amplifon outside every published definition
The excess reconciles: stripping retail out lands the manufacturer tier back at roughly $8 to $9 billion, which is the published figure almost exactly
Unit growth has decelerated from 7.7% (2023) to 4.0% (2024) to 2.1% (2025), against published CAGRs of 5.6% to 11.7%
Measured consumer prices per pair fell 42% between 2018 and 2026, following the FDA over-the-counter rule effective 17 October 2022; OTC pairs transact at $502 against $3,432 prescription private pay
Market Overview
Market Context
Hearing aids are sold twice, and the research industry sizes only the first sale. A manufacturer makes a device and sells it at a factory-gate price of a few hundred dollars; a dispenser fits it, tunes it, follows the patient up and charges a bundled price several times higher. The published market figures measure the first transaction. They are approximately right for it — our reconciliation of disclosed manufacturer revenue lands within a few hundred million dollars of Global Market Insights' $8.8 billion for 2025 — and they are roughly 3.5 times too small for the thing most readers assume a market size means. The proof is available because this industry publishes unusually well. EHIMA gives units: 23.16 million in 2025. HearingTracker's buyer survey gives measured prices: $2,694 per pair. And Demant, uniquely, reports both tiers in one statement and shows retail revenue exceeding wholesale revenue inside the same company. The structural consequence is that the four groups with manufacturing businesses are all buying their way down the chain — Demant grew retail revenue 8% in a year when its wholesale fell 2%, and Sonova has renamed its two businesses Wholesale and Retail — while a pure retailer like Amplifon operates entirely outside every published definition of the market. Underneath all of it sits the number that frames the opportunity and the failure together: 23.16 million units sold a year against the 1.5 billion people WHO counts with some degree of hearing loss.
This is the best-instrumented market in this batch and the one where a single unstated scope decision does the most damage. EHIMA's member companies sold 23.16 million hearing aids globally in 2025. Divide the published market sizes by that count and you get $380 to $652 per hearing aid — a factory-gate price. HearingTracker's survey of more than 1,100 buyers puts the measured average transaction at $2,694 a pair, or $1,347 an aid, so consumer spend on those 23.16 million units is roughly $31 billion, about 3.5 times the published figure. Demant proves the two-tier structure from inside one company: its retail revenue of DKK 10,724 million in 2025 exceeded its wholesale hearing-aid revenue of DKK 9,841 million. Four manufacturers' disclosed revenue totals about $11,769 million, which is 1.34x the published market — and the excess reconciles exactly once retail is stripped out, landing back on the manufacturer tier. We publish that tier, Global Market Insights' September 2025 series: $9.37 billion in 2026 to $13.67 billion by 2032 at 6.5%. The caution is that unit growth has decelerated to 2.1%, measured consumer prices are down 42% since 2018, and the manufacturers' own 2025 growth was roughly 2 to 3%.
Market Stage
Mature
Adoption Level
23.16 million units a year against 1.5 billion people with some hearing loss
Key Trends
Market Forecast & Data
Base Year (2026)
$9.4B
Forecast (2032)
$13.7B
CAGR (2026-2032)
6.5%
| Year | Market size ($ Billion) |
|---|---|
| 2026Base year | $9.37B |
| 2027 | $9.98B |
| 2028 | $10.63B |
| 2029 | $11.32B |
| 2030 | $12.06B |
| 2031 | $12.84B |
| 2032 | $13.67B |
Our 6.5% is Global Market Insights' own rate on its own base, and the series reproduces that rate exactly. Whether 6.5% is defensible for the manufacturer tier is the harder question, and the evidence says it sits at the optimistic end of what the disclosed record supports. Three independent series all point lower. EHIMA's unit shipments decelerated from 7.7% growth in 2023 to 4.0% in 2024 to 2.1% in 2025. HearingTracker's measured consumer price per pair fell 42% between 2018 and 2026, with over-the-counter devices transacting at $502 against $3,432 for a prescription private-pay pair — the direct consequence of the FDA rule effective 17 October 2022. And the manufacturers themselves grew roughly 2 to 3% in 2025: Demant's external wholesale revenue down 2%, WS Audiology 0% organic on reduced United States benefit coverage, GN 5% organic after 10% and 13% in the two prior years. Sonova is the exception, with Wholesale accelerating to 10.9% in local currencies in the second half of FY2025/26 on the Phonak Infinio platform, which shows that a strong product cycle can still move share within a flat market. There is a coherent route to 6.5% at the manufacturer tier: wholesale prices hold while retail margins absorb the consumer price compression, so factory-gate revenue grows faster than consumer spend. Demant's own split is exactly that pattern under strain. But that argument supports the bottom of the published range, not the 10.1% and 11.7% figures circulating on secondary sites. Readers should forecast units — which EHIMA publishes and which is decelerating — and apply their own view of wholesale price, rather than accepting any published revenue CAGR for a market whose volume growth has halved twice in two years.
Market Dynamics
- Demographic inevitability: the WHO figure Global Market Insights itself cites puts 1.5 billion people with some degree of hearing loss, against 23.16 million units sold a year
- The FDA's over-the-counter category, effective 17 October 2022, which removed the professional gatekeeping requirement for adults with perceived mild-to-moderate loss and has put devices on retail shelves at $502 a pair
- Retail vertical integration, which is where the margin now accrues: Demant's clinic revenue rose 8% in 2025 on acquisitions, and Sonova has renamed its dispensing arm Retail and reports it inside the same segment as Wholesale
- Platform refresh cycles driving replacement rather than first fittings: GN's 5% organic growth in 2025 was attributed specifically to the ReSound Vivia platform, and Sonova's second-half Wholesale acceleration to 10.9% to Phonak Infinio
- Rechargeability and connectivity as replacement triggers, which shorten the effective device life of an installed base that historically replaced every five to seven years
- Reimbursement expansion in individual markets, which moves whole cohorts at once — and whose withdrawal does the same in reverse, as WS Audiology's citation of reduced United States benefit coverage shows
Market Segmentation
By Type
- Behind-the-ear (BTE)
- Receiver-in-the-ear / receiver-in-canal (RITE/RIC)
- In-the-ear (ITE)
- In-the-canal (ITC)
- Completely-in-canal and invisible-in-canal (CIC/IIC)
- Over-the-counter and self-fitting devices
By End User
- Audiology clinics and hearing care retail networks
- Independent hearing aid dispensers
- Hospitals and ENT practices
- Big-box and warehouse retail
- Online and direct-to-consumer channels
By Application
- Sensorineural hearing loss
- Conductive and mixed hearing loss
- Age-related hearing loss (presbycusis)
- Noise-induced hearing loss
- Paediatric hearing loss
Competitive Landscape
Sonova Holding AG
Stafa, Switzerland
FY2025/26 (ended 31 March 2026, released 18 May 2026) group sales CHF 3,605.9 million, up 5.9% in local currencies and down 0.2% in Swiss francs, on continuing operations. The Hearing Instruments segment — Wholesale plus Retail — was reported at approximately CHF 3.35 billion, up 7.5% in local currencies, with Wholesale growth accelerating to 10.9% in local currencies in the second half on the Phonak Infinio and Sphere Infinio platforms. Normalised EBITA CHF 811.2 million, up 17.3% in local currencies; reported EBITA CHF 724.2 million. Consumer Hearing is being divested and is reported as discontinued operations, with FY2024/25 comparatives restated from the original CHF 3,865.4 million.
Demant A/S
Smorum, Denmark
2025 group revenue DKK 22,971 million against DKK 22,419 million, up 2% organic and 5% in local currencies. Hearing Aids external revenue — wholesale to third parties — DKK 9,841 million, down 2% reported from DKK 10,022 million; total Hearing Aids revenue including DKK 2,632 million of internal sales to its own retail, DKK 12,473 million. Hearing Care, the retail clinic business, DKK 10,724 million, up 8% reported on acquisitions. EBIT before special items DKK 3,960 million at a 17.2% margin. 2026 guidance of 3-6% organic growth. The company cited slower-than-normal hearing aid market growth and intense competition as drags on profitability.
WS Audiology A/S
Lynge, Denmark
FY2024/25 revenue EUR 2,579 million — roughly $2,796 million at our own approximate conversion — at 0% organic growth against 10% the prior year, attributed to broader economic slowdowns and reduced benefit coverage in the United States. Fourth-quarter revenue EUR 621 million at -1% organic, with EBITDA before special items of EUR 119 million at a 19.2% margin. Launches included Signia Insio Charge&Go CIC IX, Motion Charge&Go IX and Pure Charge&Go BCT IX, plus the Widex ALLURE platform and Widex Compass Cloud fitting software. FY2025/26 guidance of 0% to 4% organic growth, with first-half revenue of EUR 1.257 billion at flat organic growth.
GN Store Nord A/S (GN Hearing)
Ballerup, Denmark
Hearing division 2025 revenue DKK 7,214 million against DKK 7,104 million — roughly $1,048 million at our own approximate conversion — including a -1% impact from mergers and acquisitions and -2% from foreign exchange, with 5% organic growth after 10% in 2024 and 13% in 2023. Growth attributed to the ReSound Vivia platform, which the company says enabled record-high market share across various markets. 2026 Hearing division guidance of 3% to 7% organic revenue growth. A divisional profit figure circulating with these results does not reconcile against the revenue line, so no GN profit figure is used here.
Starkey Hearing Technologies
Eden Prairie, Minnesota, United States
Privately held hearing aid manufacturer with a United States manufacturing base, competing across the prescription channel alongside the four European groups. Publishes no revenue, unit or share figures, so it enters no arithmetic in this report.
Amplifon S.p.A.
Milan, Italy
Operates a large international network of hearing care clinics, dispensing devices made by the four manufacturing groups and Starkey. Its revenue is retail dispensing and audiological services, the tier that Demant's own accounts show to be larger than wholesale and that no published hearing aid market size counts.
Recent Developments
Reported that member companies collectively sold 23.16 million hearing aids globally in 2025, a 2.1% increase on 2024 — a sharp deceleration from 22.69 million in 2024 (+4.0%) and 21.81 million in 2023 (+7.7%), and far below every published revenue CAGR for the market.
Reported FY2025/26 results on 18 May 2026 with group sales of CHF 3,605.9 million, up 5.9% in local currencies and down 0.2% in Swiss francs, Wholesale growth accelerating to 10.9% in local currencies in the second half, and normalised EBITA up 17.3% to CHF 811.2 million — alongside a decision to divest Consumer Hearing, now reported as discontinued operations, and a renaming of Hearing Instruments to Wholesale and Audiological Care to Retail.
Published its 2025 annual report showing group revenue of DKK 22,971 million with external wholesale hearing-aid revenue down 2% to DKK 9,841 million while Hearing Care retail revenue rose 8% to DKK 10,724 million — retail exceeding wholesale inside the same company — and cited slower-than-normal hearing aid market growth and intense competition as drags on profitability.
Reported 2025 Hearing division revenue of DKK 7,214 million with 5% organic growth, following 10% in 2024 and 13% in 2023, attributed to the ReSound Vivia platform, and guided the division to 3% to 7% organic growth for 2026.
Reported FY2024/25 revenue of EUR 2,579 million at 0% organic growth, against 10% the prior year, attributing the flat result to broader economic slowdowns and reduced benefit coverage in the United States, and guided FY2025/26 to 0% to 4% organic growth.
Published the over-the-counter hearing aid final rule at 87 FR 50698 on 17 August 2022, effective 17 October 2022, creating an OTC category for air-conduction hearing aids for adults aged 18 and over with perceived mild-to-moderate hearing loss and repealing the prior conditions for sale, with devices already legally marketed required to comply by 14 April 2023 — the regulatory event behind a 42% fall in measured consumer prices since 2018.
Regulatory Landscape
Research Methodology
Secondary research
- European Hearing Instrument Manufacturers Association (EHIMA), global hearing aid sales statistics — member companies sold 23.16 million units globally in 2025 (+2.1%), 22.69 million in 2024 (+4.0%) and 21.81 million in 2023 (+7.7%)
- Global Market Insights, Hearing Aids Market, report GMI5082, published September 2025 — $8.3B (2024), $8.8B (2025), $15.5B (2034), 6.5% (2025-2034), with a published history from 2021, product, patient and channel segmentation and regional figures
- Demant A/S, Annual Report 2025 and review of H2 2025 — group revenue DKK 22,971M; Hearing Aids external DKK 9,841M (-2%); Hearing Aids including internal sales DKK 12,473M; Hearing Care retail DKK 10,724M (+8%); EBIT before special items DKK 3,960M at 17.2%
- Sonova Holding AG, FY2025/26 results, 18 May 2026 — group sales CHF 3,605.9M (+5.9% local currencies) on continuing operations; Hearing Instruments segment approximately CHF 3.35B; Wholesale +10.9% local currencies in H2; Consumer Hearing divested and reported as discontinued
- Sonova Holding AG, Annual Report 2024/25 — group sales CHF 3,865.4M (+7.6% local currencies, +6.6% in CHF) before restatement for the Consumer Hearing divestment
- WS Audiology A/S, FY2024/25 annual results — revenue EUR 2,579M at 0% organic growth; Q4 EUR 621M at -1% organic with EBITDA before special items of EUR 119M at 19.2%; FY2025/26 guidance 0-4% organic
- GN Store Nord A/S, GN Annual Report 2025 — Hearing division revenue DKK 7,214M (2024: DKK 7,104M) with 5% organic growth after 10% in 2024 and 13% in 2023; 2026 guidance 3-7% organic
- HearingTracker, What is the true cost of hearing aids in 2026 — survey of more than 1,100 buyers: $2,694 average per pair against $4,672 in 2018; $502 per pair over-the-counter against $3,432 prescription private pay; Costco $1,674 per pair
- U.S. FDA, Medical Devices; Ear, Nose, and Throat Devices; Establishing Over-the-Counter Hearing Aids, final rule, 87 FR 50698, published 17 August 2022, effective 17 October 2022, compliance for legacy devices by 14 April 2023
- Ken Research — $9.08B (2025) to $14.57B (2032) at 7.00%; MarketsandMarkets report 182461673 — $10.35B (2025) at 6.8% to 2030; Meticulous Research — $13.04B by 2032 at 5.7%; Fortune Business Insights via secondary sites — $15.11B (2025) to $29.58B (2032) at 10.1%, with a conflicting second version at $34.76B and 11.7%
Validation: The headline is one publisher's own base advanced at its own rate, labelled as interpolation: Global Market Insights' $8.8 billion for 2025 becomes $9.37 billion for 2026 and $13.67 billion for 2032 at 6.5%. The internal check is that the implied rate between our endpoints is 6.50%, identical to the stated rate. GMI was chosen because it carries a stated publication date and the longest published history in the set — five dated annual values from 2021 to 2025 — because it is the only source in the set read directly from the publisher's own page rather than through a search summary or secondary site, and because its $8.8 billion is the figure our reconciliation of disclosed manufacturer revenue lands on almost exactly. Five grounding tests were run. First, price per unit: EHIMA member companies sold 23.16 million hearing aids globally in 2025, so the published totals work out at $380 per aid on GMI's figure, $447 on MarketsandMarkets' and $652 on the Fortune figure circulating on secondary sites. HearingTracker's survey of more than 1,100 buyers puts the measured average transaction at $2,694 per pair, or $1,347 per aid, so 23.16 million units at consumer prices is roughly $31.2 billion — about 3.5 times GMI's total. The published figures are therefore manufacturer-tier revenue, and no publisher in the set says so. Second, Demant proves the two tiers from inside one company: in 2025 its Hearing Care retail revenue of DKK 10,724 million exceeded its external wholesale hearing-aid revenue of DKK 9,841 million, and its own retail arm bought DKK 2,632 million of aids internally while selling DKK 10,724 million of hearing care. Third, summing disclosed revenue: Sonova CHF 3,605.9 million, Demant DKK 22,971 million, WS Audiology EUR 2,579 million and GN's Hearing division DKK 7,214 million total about $11,769 million at our own approximate conversions, which is 1.34 times GMI's $8.8 billion, 1.30 times Ken Research's $9.08 billion and 1.14 times MarketsandMarkets' $10.35 billion — with Starkey, privately held, not in the sum and Amplifon, a pure retailer, outside every published definition. Fourth, the reconciliation: stripping retail out where it is disclosed gives Demant's wholesale at about $1,430 million, GN at $1,048 million and WS Audiology at about $2,796 million, totalling $5,274 million, to which Sonova's Wholesale and Starkey must be added; at plausible magnitudes for those two the manufacturer tier totals roughly $8.1 to $8.8 billion, which is GMI's figure. So the published figures are approximately right for the tier they measure and roughly 3.5 times too small for the tier a reader assumes. Fifth, a coherence test on growth: EHIMA unit growth decelerated from 7.7% to 4.0% to 2.1% across 2023-2025, measured consumer prices fell 42% from 2018 to 2026, and the manufacturers' own 2025 growth was roughly 2 to 3% — Demant's external wholesale down 2%, WS Audiology 0% organic, GN 5% organic — against published CAGRs of 5.6% to 11.7%. These are scope and plausibility tests, not market estimates. All currency conversions are ours at approximate rates implied by the USD figures the sources' own coverage printed alongside the local-currency ones; HearingTracker's prices are dated 2026 against our 2025 price base and are a survey of self-selected buyers rather than an average selling price; EHIMA's series covers member companies only and is therefore a floor on world units, with no published figure for members' share of global volume; the Sonova Wholesale and Starkey magnitudes used in the fourth test are our own and are published nowhere, and they appear in the notes file only; and dividing company revenue into a published market total compares differently constructed numbers. Regional, country and channel splits are published as empty arrays or plain strings: the only source offering them presents no method, and its own e-commerce figure of $3.2 billion for 2024 — 38.6% of its total — is not credible in an industry where Demant's clinic revenue alone is DKK 10,724 million. No vendor market share is published because none is disclosed, and the trade commentary putting Sonova between 25% and 31% carries no method.
Strategic Takeaways
Decide which tier you mean. The published $8.8 billion is manufacturer revenue at about $380 per aid. Consumer spend on the same 23.16 million units is roughly $31 billion at measured transaction prices. The gap is the dispensing channel and no publisher labels it.
Use the unit series, not the revenue series. EHIMA publishes global member unit sales, and they grew 7.7%, then 4.0%, then 2.1% across 2023-2025 — a deceleration no published revenue CAGR reflects.
Read Demant's two revenue lines together. Retail at DKK 10,724 million rising 8% against wholesale at DKK 9,841 million falling 2%, in the same company, in the same year, is the clearest single piece of evidence about where the money in this industry has moved.
Note that four manufacturers already disclose more revenue than three of the five published markets contain — and that Starkey is private and Amplifon manufactures nothing, so neither appears in any of them.
Treat the FDA over-the-counter rule as a price event, not a volume event. OTC pairs transact at $502 against $3,432 prescription, measured prices are down 42% since 2018, and units grew 2.1% last year. That combination does not produce a double-digit revenue CAGR.
Frequently Asked Questions
Related research
Reports in the same field, each with its base-year figure and the growth rate it is published at.
- Medical DevicesNeuromodulation Market$9.4B · 9.35% CAGR
- Medical DevicesFemtech Market$9.8B · 14.2% CAGR
- Medical DevicesGlobal Continuous Glucose Monitoring Market$9.8B · 15.8% CAGR
- Medical DevicesSleep Apnea Devices Market$7.5B · 7.6% CAGR
- Medical DevicesGlobal Surgical Robotics Market$12.9B · 14.5% CAGR
- Medical DevicesAdvanced Wound Care Market$14.4B · 7.6% CAGR